Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

handshake_2

Curium Pharma announces acquisition of Monrol

April 3, 2025 Manufacturing and Production, Research and Development Curium Pharma, Monrol, Oncology, acquisition, nuclear medicine, radiopharmaceutical products

Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine player. With facilities across Europe …
News

GRI Bio announces two global patents granted for Europe and Japan

April 2, 2025 Research and Development Chronic Diseases, GRI Bio, autoimmune diseases, biotech, fibrotic diseases, inflammatory diseases, patent

GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global …
News

Usama Dar appointed as chief product and technology officer at CluePoints

April 2, 2025 Research and Development Pharmacy, clinical trial analysis, cluepoints, pharma, research and development

CluePoints has appointed Usama Dar as its new chief product and technology officer, effective 1 April 2025. This follows Dar’s …
Appointment

Dupixent approved as first biologic medicine in Japan for COPD patients

April 2, 2025 Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …
News

Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial

April 1, 2025 Research and Development Cardiology, Novo Nordisk, cardiometabolic diseases, research and development

Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse …
News

Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint

April 1, 2025 Research and Development Corcept Therapeutics, Oncology, ovarian cancer, research and development

Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase …
News

Secarna Pharmaceuticals to announce positive new data at cancer research conference

April 1, 2025 Research and Development Oncology, Secarna Pharmaceuticals, oncology, research and development

Secarna Pharmaceuticals will present new preclinical data with its lead programme SECN-15 at the American Association for Cancer Research (AACR) …
News

Qfitlia approved by FDA to treat haemophilia A or B

March 31, 2025 Research and Development FDA, Haematology, Sanofi, haemophilia, pharma

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …
News

Winners announced for 2025 PM Society Awards

March 31, 2025 Industry Associations, Research and Development Pharmacy, awards, pharma industry, pm society

The pharma marketing and healthcare communications industry gathered for the 39th PM Society Awards on 14 March 2025, which celebrates …
News

FDA grants fast track designation to chlamydia vaccine candidate

March 28, 2025 Research and Development FDA, Infections and infestations, Sanofi, chlamydia, vaccination

The US Food and Drug Association (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention …
News
lungs

Pierre Fabre announces investments and partnerships in lung cancer research

March 27, 2025 Research and Development Oncology, Pierre Fabre Laboratories, lung cancer treatment, oncology

Pierre Fabre Laboratories has announced investment and partnership plans to improve the lives of lung cancer patients with unmet needs. …
News

Allegro shares promising preclinical results for osteoarthritis treatment

March 26, 2025 Clinical Trial Services, Research and Development Allegro, Orthopaedics, biomedical, clinical studies, osteoarthritis

Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is …
News

Pharming Group doses first patient in phase 2 trial of leniolisib in CVID

March 26, 2025 Clinical Trial Services, Research and Development CVID, Immunology, Pharming Group, clinical trial, common variable immunodeficiency, immunodeficiency

Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib in …
News

Recce Pharmaceuticals reports positive phase 2 data for skin infection drug

February 17, 2025 Research and Development Recce, Skin, diabetes, skin, skin infections

Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment …
News
1200px-european_flag_in_karlskrona_2011

European Commission launches new Biotech and Biomanufacturing Hub

February 3, 2025 Research and Development Biomanufacturing, Corporate, European Commission, Hub, european union

The European Commission has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small- to medium-sized …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026